Andreas Müller

Andreas Müller′s practice focuses on public and private mergers & acquisitions, private equity and capital markets. He also advises on matters of corporate governance and executive compensation, as well as corporate law and securities regulation. He heads the firm's Executive Compensation team, and is the chair of the editorial board of a legal periodical on corporate and capital markets law (Schweizerische Zeitschrift für Gesellschafts- und Kapitalmarktrecht, GesKR). Winner of the Lexology Client Choice Awards 2022 in "Corporate Governance" and 2023/2024 in "M&A and Governance".

• Advised Novo Nordisk (NYSE: NVO) on its USD 11 bn acquisition of three manufacturing sites from Novo Holdings A/S, which followed the completion of Novo Holdings' acquisition of Catalent (NYSE: CTLT)
• Regularly advises issuers and investors on equity financings, including biotech Windward Bio on its USD 200 m Series A financing, biotech Noema on its USD 147 m Series B financing round and extension, hardtech Kandou on its USD 100 m Series E financing, insurtech wefox on its USD 55 m Series D extension funding round, as well as its Series D funding round re-sulting in a post-money valuation of USD 4.5bn, biotech VectivBio on all its financings; hard discounter DALI Discount on all its financings; and Novo Holdings on its investment of bio-tech Alentis, Hevolution Foundation on its investment in biotech Vandria, and General Catalyst on its financing of software company SonarSource
• Advised Liberty Global and Sunrise on the spin-off and listing of Sunrise on the SIX and NASDAQ
• Advised Pollen Street Capital on its acquisition of Etops Group
• Advised on the sale of Biopas to Swixx Biopharma
• Advised Galderma on its IPO on SIX
• Advised Müller Martini on its acquisition of Hunkeler
• Advised Credit Suisse (SIX: CSGN) on its merger with UBS (SIX: UBSG)
• Advised VectivBio (Nasdaq: VECT) on the public cash tender offer from Ironwood Pharmaceuticals (Nasdaq: IRWD), and previously on VectivBio's follow-on public offering and concurrent private placement, its acquisition of Comet Therapeutics, its USD 75 m loan facility with Kreos Capital, and its IPO on Nasdaq
• Advised Luzerner Kantonalbank AG on its CHF 489m rights offering
• Advised Dufry AG (SIX: DUFN) on its cross-border strategic combination with Autogrill (BIT: AGL) and related equity and debt financings; as well as all its equity and debt financings
• Advised AEQUITA on its acquisition of Saint-Gobain's Swiss Glassolutions Business
• Advised Tiedemann Group on its business combination with Alvarium Investments and the SPAC Cartesian Growth Corporation, to form AlTi Global (Nasdaq: ALTI)
• Advised AMF Medical and its shareholders on the sale of AMF Medical to Tandem Diabetes Care

• Capital markets: Equity
• Corporate Governance
• M&A
• Private Equity

• Consumer goods
• Financial services
• Healthcare / Life Sciences
• Healthcare
• Pharma and life sciences
• Tech

• New York Bar (2012)
• Zurich Bar (2010)

• Master of Laws (LL.M.), Harvard Law School (2012)
• Dr. iur., University of Basel (2013)